Retrospective assessment of the Lung-RADS performance in the Silesian Lung Cancer Screening Pilot Study by Wachuła, Ewa et al.
1ORIGINAL ARTICLE
Address for correspondence:
Lek. Ewa Wachuła
Klinika Onkologii, Wydział Lekarski
z Oddziałem Lekarsko-Dentystycznym 
w Zabrzu
Śląski Uniwersytet Medyczny w Katowicach
ul. Ceglana 35, 40–514 Katowice
Phone: +48 32 358 13 48
Fax: +48 32 358 12 00
e-mail: wachula.ewa@gmail.com
Ewa Wachuła1, Sylwia Szabłowska-Siwik1, Damian Czyżewski2, Jerzy Kozielski3,  
Wojciech Rogowski4, Mariusz Adamek2
1Department of Oncology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland
2Department of Thoracic Surgery, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland
3Department of Lung Diseases and Tuberculosis, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland
4NZOZ Magodent, Oncology Hospital, Warszawa, Poland
Retrospective assessment of Lung-RADS® 
performance in the Silesian Lung Cancer 
Screening Pilot Study
ABSTRACT
Background. A high percentage of false positive results, observed in lung cancer screening studies with low-dose 
computed tomography (LDCT), caused the modification of radiological assessment methods. According to the 
International Early Lung Cancer Action Program (IELCAP) all non-calcified nodules with a dimension ≥ 4 mm 
were considered as positive. Implementation of classification the Lung CT screening Reporting and Data System 
(Lung-RADS®) recommends additional testing only for nodules ≥ 6 mm, which reduced of false positive results.
Methods. We provided a retrospective analysis of 601 LDCT scans, in asymptomatic volunteers of Pilot Silesian 
Study of Early Lung Cancer Detection, with at least 20 pack-years of cigarette smoking. The analysis of non- and 
invasive interventions was done. Assessment of nodules according to the Lung-RADS® system was done. Then 
the percentage of interventions that could be avoided using the Lung-RADS® criteria was estimated.
Results. In total, 1016 nodules were identified in 265 participants. The positive result of screening was defined as 
a presence of solid or part-solid nodule ≥ 5 mm and ≥ 8 mm in the case of a nonsolid nodule in line with the IELCAP 
protocol. Screening based on the IELCAP protocol resulted in 200 positive results and based on Lung-RADS® in 
the 116 positives. The frequency of lung cancers among participants with a positive result was 7 of 200 (4.0%) 
(95% CI: 1.0%, 6.0%) for IELCAP and 7 of 116 (6.0%) (95% CI: 2.7%, 9.3%) for Lung-RADS®. The Lung-RADS® 
criteria reduced number of non- and invasive procedures by 48.8% and 24.1%, compared to IELCAP protocol.  
Conclusions. Adopting the Lung-RADS® classification system may reduce harms and improve the efficiency of 
lung cancer screening programs. 
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Introduction 
Cancer is a leading cause of death worldwide, account-
ing for an estimated 9.6 million deaths in 2018. Screening 
programs aimed at detecting lung cancer target high-risk 
persons who need consistent monitoring to enable early 
diagnosis of the disease. The recommended screening test 
for lung cancer is low-dose computed tomography (LDCT) 
for persons who are at high risk of lung cancer because of 
cigarette smoking history and age [1]. In the case of detection 
of a pulmonary nodule, additional evaluations are needed 
to determine whether lung cancer is present. Screening 
protocols standardise interpretation of screen-detected 
nodules and harmonise nodule management. The Inter-
national Early Lung Cancer Action Program (IELCAP) 
and the Lung CT screening Reporting and Data System 
(Lung-RADS®) are two protocols for lung cancer screening 
programs [2, 3]. The primary evidence of lung cancer screen-
ing effectiveness came from the National Lung Screening 
Trial (NLST) conducted without a protocol for management 
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of nodules [1]. The IELCAP showed that increased nodule 
size cut-offs decreased the fervency of positive results in the 
baseline screening, with only a few missed cancer cases 
[2, 4] in comparison to the method used in the National 
Lung Screening Trial [1]. It substantially reduced diag-
nostic workload. Most recently, the American College 
of Radiology introduced the Lung-RADS® protocol to 
reduce the frequency of false-positives without a signifi-
cant effect on screening sensitivity [3, 5].
Population oriented screening for lung cancer has 
significant socio-economic consequences, especially 
for big countries with large populations of smokers. In 
Poland, there are about 8.7–9 million smokers (31% 
of adult men, of whom 26% smoke regularly, and 21% 
of adult women, of whom 17% regularly smoke) per 
38.4 million inhabitants [6, 7]. Such a large-scale screen-
ing is a complex organisational challenge and is associ-
ated with both benefits and harms. Planning a screen-
ing program requires an optimal balance between the 
benefits, harms, and/or cost-effectiveness. Among many 
factors, categorisation of many small pulmonary nodules 
as negative screens substantially reduces the number of 
false-positives and the subsequent need for additional 
scans and invasive procedures. 
The Pilot Silesian Study for Early Lung Cancer 
Detection with LDCT used IELCAP as the screening 
protocol [8]. To assess how the increase of the nodule 
size threshold would affect screening performance, 
we retrospectively applied Lung-RADS® criteria to 
nodule-level baseline results of the screening. 
Material and methods
The Pilot Silesian Study included 602 asymptomatic 
adults with a history of tobacco smoking of at least 
20 pack-years and former smokers who quit smoking 
within the last 15 years before the study visit. In our 
protocol 20 pack-years was adopted as the cut-off point, 
due to the inclusion in the cohort of people addition-
ally exposed to other factors, e.g. occupational (miners, 
asbestos workers, steel workers) and environmental (air 
pollution in the areas of Upper Silesia). One patient was 
excluded from analysis because of a diagnosis of symp-
tomatic lung cancer. In one patient the cancer diagnosis 
was missed due to false-negative result of screening [8]. 
At baseline, the positive result of screening was defined 
as the presence of a solid or part-solid nodule ≥ 5 mm, 
and ≥ 8 mm in the case of a nonsolid nodule, in line with 
the IELCAP protocol [2]. The sizes for nodules were 
computed based on the measurements performed in two 
transverse sections. Positive results were followed up 
with subsequent scans and different invasive procedures 
(e.g. bronchoscopy, endobronchial ultrasound-guided 
biopsy, transthoracic biopsy) aiming for lung cancer 
verification (true-positive). Other nodules confirmed in 
histopathological analyses as benign lesions were defined 
as false-positive results of screening [8]. In this analysis, 
we focused on the first-round results; the algorithm of 
the procedure is presented in Table 1.
To assess the effect of the Lung-RADS® protocol on 
the performance LDCT screening in the Silesian Pilot 
Study [8], the criteria of the screening protocol [3] were 
retrospectively applied to nodule-level data and com-
pared with the primary IELCAP protocol-based data. 
The comparison included some imaging and invasive 
procedures performed within alternative screening pro-
tocols, sensitivity, and specificity of protocols. Sensitivity 
was the percentage of screenings with cancer present that 
were positive; specificity was the percentage of screenings 
with cancer absent that were negative. The comparison 
was limited to the results of the baseline LDCT scans.
Results
The Pilot Silesian Study database lists in total 
1016 nodules with a diameter ≥ 3 mm detected in 
265 persons during the baseline screening. In this set 
110 solid, 46 part-solid, and 44 nonsolid nodules were 
classified as positive results according to the IELCAP 
protocol. When the Lung-RADS® protocol was applied, 
the number of positive screening results decreased to 
73 solid, 19 part-solid, and 24 nonsolid nodules.
Table 1. Algorithm of the work-up procedures based on the IELCAP protocol
Detected lesion Recommended LDCT interval or further work-up
SPN £ 5 mm LDCT in 12 months
SPN 6–7 mm LDCT in 6 months
SPN 8–14 mm solid or part-solid LDCT in 3 months
SPN ≥ 15 mm — CT-PET
— Biopsy (CT- or US-guided TTNB, EBUS-TBNA, rEBUS-TBNA)
— Suspected infectious lesion; antibiotic course; f/u LDCT in 1 month
Intrabronchial SPN Bronchoscopy
LDCT negative result — further CT not required in the pilot study 
LDCT positive result — one solid or partsolid nodule ≥ 5 mm or one nonsolid nodule ≥ 20 mm (annual screening with LDCT in 12 months)
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Lung cancer was diagnosed in seven patients after 
the baseline screening. In one patient two independent, 
synchronous cancers were diagnosed (large-cell carci-
noma and small-cell lung carcinoma). The malignant 
lesions had an average diameter of 20.25 mm. All were 
solid nodules. It the case of one person a 15 mm solid 
nodule was missed at baseline screening and detected 
in the subsequent scan (false negative result). A change 
in the scanning protocol from IELCP to Lung-RADS® 
did not result in changes in the number of true-positive 
cancer cases or missed (false negative) malignant lesions. 
Screening based on the IELCAP protocol resulted 
in 200 positive results and based on Lung-RADS® in the 
116 positives. Both screening protocols had the same sensi-
tivity of 87.5%, and the Lung-RADS® protocol had higher 
specificity of 81.8% compared to 67.5% in IELCAP. The 
frequency of lung cancers among participants with a posi-
tive result diagnosed in the baseline LDCT scan (positive 
predictive value) was 7 of 200 (4.0%) [95% confidence 
interval (CI): 1.0%, 6.0%] for IELCAP and 7 of 116 (6.0%) 
(95% CI: 2.7%, 9.3%) for Lung-RADS®. 
Each positive screening result indicated the necessity of 
follow-up with the use of noninvasive and/or invasive pro-
cedures aiming for further monitoring of detected nodules 
and diagnosis. Table 2 shows screening-resultant diagnostic 
procedures performed according to the IELCAP protocol 
and in the case of use of the Lung-RADS® protocol. The 
lower number of false positive screening results under the 
Lung-RADS® protocol allowed us to avoid some diag-
nostic procedures in comparison to IELCAP. Use of the 
Lung-RADS® criteria allowed us to reduce the number 
of noninvasive procedures by 48.8% and invasive proce-
dures by 24.1%, compared to IELCAP-based screening at 
baseline. Avoidance of subsequent procedures concerned 
persons with nodules of the second category (13 noninva-
sive and two invasive procedures avoided) and category 
3 (17 noninvasive and three invasive procedures avoided). 
Discussion
In cases of malignant nodules, the early diagnosis 
of lung cancer could provide a safe and definitive solu-
tion. Understanding the clinical significance of numer-
ous detected pulmonary nodules in population-level 
screening initiatives is an important challenge of their 
optimal management, reducing harm, and financial 
aspects. 
The current analysis addressed the relevance of 
the nodule size on the performance of two lung cancer 
screening protocols. Screening based on the IELCAP 
protocol showed that the risk of malignancy in solid nod-
ules < 5 mm diameter is ≤ 1% [4]. In the Lung-RADS® 
protocol, solid and part-solid nodules < 6 mm are 
indicated as benign appearance, with < 1% chance 
of malignancy and with follow-up after 12 months 
[5, 9]. Applying the Lung-RADS® protocol to the 
IELCAP-based screening results reduced the number 
of false-positive results with no decrease of sensitivity. 
It suggests better performance for Lung-RADS® than 
IELCAP as an element of LDCT screening. The previ-
ous study showed a similar effect on the false-positive 
result rate when Lung-RADS® criteria were applied 
to the results of the National Lung Screening Trial [8]. 
However, in contrast to the current analysis, sensiti-
vity also decreased in that study, increasing the risk of 
false-negative results under the Lung-RADS® protocol 
[8]. All pulmonary nodules identified in the Silesian Pilot 
Study were large lesions categorised as 4B at baseline 
scans, with > 15% risk of cancer. There was a two-fold 
difference between the average diameter of malignant 
lesions identified in the National Lung Screening Trial 
and the Silesian Pilot Study (9.9 vs. 20.2 mm), which 
explains the lack of increase in the rate of false negative 
results in the current analysis. There is an urgent need 
to adapt the European and American guidelines and 
recommendations to Polish conditions and consider the 
possibility of implementation of a lung cancer screening 
program [10].
Use of the Lung-RADS® protocol may significantly 
reduce the burden of procedures. In most persons 
with nodules of categories 2 and 3 it was possible to 
avoid subsequent chest computed tomography exams 
and bronchoscopies. Overall it was possible to avoid 
almost half of the noninvasive and every fourth invasive 
procedure/s after the baseline screening. Reducing 
the number of unnecessary follow-ups is important, 
especially in countries with many potential candidates 
Table 2. Diagnostic procedures with the IELCAP and Lung-RADS® protocols
IELCAP protocol, 
n
Lung-RADS® 
protocol, n
Avoided positive 
screenings/procedures, n (%)
Number of positive screening results 200 116 84 (42.0)
Follow-up chest CT scans 58 28 30 (48.8)
Bronchoscopy 16 11 5 (31.2)
Endobronchial ultrasound 5 4 1 (20.0)
Transthoracic biopsy 8 7 1 (12.5)
4OncOlOgy in clinical practice 2020, Vol. 16, No. x
for the screening program and its associated significant 
financial effort. 
It is important to note the limitations of the analy-
sis. The major limitation is that the analysis was retro-
spective and performed on a relatively small sample size 
compared to other screening prospective studies [1]. 
There is a potential measurement inaccuracy leading to 
variability in the size of nodules. The analysis was limi-
ted to the baseline screening; thus, conclusions should 
be limited to the initial screening. It is not only nodule 
size that drives its management but also the volume 
and growth rate, which can be measured in a series of 
subsequent scans [11]. 
Adopting the Lung-RADS® classification system 
may reduce harm and improve the efficiency of lung 
cancer screening programs. The initial observation of 
the advantages of the Lung-RADS® protocol should be 
confirmed in a prospective setting. 
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